Application of the CMO methodology to the improvement of primary adherence to concomitant medication in people living with-HIV. The PRICMO Project
Por:
Morillo-Verdugo, R, Velez-Diaz-Pallares, M, Garcia-Valdecasas, M, Fernandez-Espinola, S, Ferrandez, J, Navarro-Ruiz, A and Grupo Trabajo Proyecto PRICMO
Publicada:
1 oct 2023
Ahead of Print:
1 oct 2023
Resumen:
Objective: To determine the effectiveness of a pharmaceutical care intervention based on the CMO methodology (Capacity, Motivation and Opportunity) in improving primary adherence to concomitant treatment in HIV+ patients on antiretroviral treatment.
Method: This was a longitudinal prospective multicenter study carried out between September 2019 and September 2020, which included HIV+ patients older than 18 years who were on antiretroviral treatment and were taking concomitant medications. Demographic, clinical, and pharmacotherapeutic variables were collected. As required by the CMO methodology, all patients were followed for 6 months and stratified into three levels of care. Individualized pharmaceutical care was provided according to the interventions established for each level. At every consultation, a motivational interview was conducted based on each patient's alignment with and achievement of their pharmacotherapeutic objectives. A website was developed to deal with the opportunity pillar. The main variable was the percentage of patients considered primary adherents to the prescribed concomitant medication. Adherence over the six months prior to the study was compared to adherence at the end of the study. Additionally, the percentage of patients considered secondary adherents to concomitant treatment and antiretroviral treatment during the 6 months prior to the start of the study was compared to the percentage of such patients at the end of the study. Adherence was measured based on dispensation records and specific validated questionnaires. Patients were only considered adherent if they were deemed adherent by both methods.
Results: A total of 61 patients were included in the study, 72% male. Median age was 53 years and the median number of concomitant drugs prescribed was 7. A total of 60.6% of patients were polymedicated. The percentage of patients considered primary non- adherent was 52.5% at baseline (n = 32) and 4.9% (n = 3, p < 0.001) at the end of the study. Secondary adherence to both concomitant medication (41.6% vs 88.3%) and antiretroviral treatment (85.2% vs 95.1%) improved at the end of the study (p < 0.0001).
Conclusions: Pharmaceutical care based on the CMO methodology significantly improved both primary and secondary adherence to concomitant drugs and to antiretroviral treatment.
Filiaciones:
Morillo-Verdugo, R:
Hosp Univ Valme, AGS Sevilla, Serv Farm, Seville, Spain
Velez-Diaz-Pallares, M:
Hosp Ramon & Cajal, Serv Farm, Madrid, Spain
Garcia-Valdecasas, M:
Hosp Principe Asturias, Serv Farm, Alcala De Henares, Madrid, Spain
Fernandez-Espinola, S:
Hosp Serrania Ronda, Serv Farm, Ronda, Malaga, Spain
Ferrandez, J:
Hosp Getafe, Serv Farm, Getafe, Madrid, Spain
:
Hosp Elche, Serv Farm, Elche, Alicante, Spain
Open Access
|